147 related articles for article (PubMed ID: 31687889)
1. Impurity Qualification Toxicology Study for a 2'-O-Methoxyethyl-Modified Antisense Inhibitor in Mice.
Kim TW; Papagiannis C; Capaldi D; McPherson AK; Mahdi F; Luu N; Rodriguez AA; Hoffmaster C; Serota D; Henry SP
Nucleic Acid Ther; 2020 Feb; 30(1):14-21. PubMed ID: 31687889
[TBL] [Abstract][Full Text] [Related]
2. Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice.
Zanardi TA; Kim TW; Shen L; Serota D; Papagiannis C; Park SY; Kim Y; Henry SP
Nucleic Acid Ther; 2018 Aug; 28(4):233-241. PubMed ID: 29708844
[TBL] [Abstract][Full Text] [Related]
3. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
[TBL] [Abstract][Full Text] [Related]
4. THERAPEUTIC OLIGONUCLEOTIDES, IMPURITIES, DEGRADANTS, AND THEIR CHARACTERIZATION BY MASS SPECTROMETRY.
Pourshahian S
Mass Spectrom Rev; 2021 Mar; 40(2):75-109. PubMed ID: 31840864
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.
Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM
Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341
[TBL] [Abstract][Full Text] [Related]
6. Semi-quantitative determination of co-eluting impurities in oligonucleotide drugs using ion-pair reversed-phase liquid chromatography mass spectrometry.
Roussis SG; Cedillo I; Rentel C
J Chromatogr A; 2019 Jan; 1584():106-114. PubMed ID: 30473112
[TBL] [Abstract][Full Text] [Related]
7. Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense Oligonucleotide.
Shen L; Engelhardt JA; Hung G; Yee J; Kikkawa R; Matson J; Tayefeh B; Machemer T; Giclas PC; Henry SP
Nucleic Acid Ther; 2016 Aug; 26(4):236-49. PubMed ID: 27140858
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
Kim TW; Kim KS; Seo JW; Park SY; Henry SP
J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663
[TBL] [Abstract][Full Text] [Related]
9. Impurities in Oligonucleotide Drug Substances and Drug Products.
Capaldi D; Teasdale A; Henry S; Akhtar N; den Besten C; Gao-Sheridan S; Kretschmer M; Sharpe N; Andrews B; Burm B; Foy J
Nucleic Acid Ther; 2017 Dec; 27(6):309-322. PubMed ID: 29125795
[TBL] [Abstract][Full Text] [Related]
10. Strategies for the investigation and control of process-related impurities in drug substances.
Argentine MD; Owens PK; Olsen BA
Adv Drug Deliv Rev; 2007 Jan; 59(1):12-28. PubMed ID: 17189658
[TBL] [Abstract][Full Text] [Related]
11. Calculating qualified non-mutagenic impurity levels: Harmonization of approaches.
Graham JC; Powley MW; Udovic E; Glowienke S; Nicolette J; Parris P; Kenyon M; White A; Maisey A; Harvey J; Martin EA; Dowdy E; Masuda-Herrera M; Trejo-Martin A; Bercu J
Regul Toxicol Pharmacol; 2021 Nov; 126():105023. PubMed ID: 34363920
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2.
Zanardi TA; Han SC; Jeong EJ; Rime S; Yu RZ; Chakravarty K; Henry SP
J Pharmacol Exp Ther; 2012 Nov; 343(2):489-96. PubMed ID: 22915769
[TBL] [Abstract][Full Text] [Related]
13. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides.
Prakash TP; Kawasaki AM; Wancewicz EV; Shen L; Monia BP; Ross BS; Bhat B; Manoharan M
J Med Chem; 2008 May; 51(9):2766-76. PubMed ID: 18399648
[TBL] [Abstract][Full Text] [Related]
14. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.
Geary RS; Wancewicz E; Matson J; Pearce M; Siwkowski A; Swayze E; Bennett F
Biochem Pharmacol; 2009 Aug; 78(3):284-91. PubMed ID: 19393225
[TBL] [Abstract][Full Text] [Related]
15. Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88.
Senn JJ; Burel S; Henry SP
J Pharmacol Exp Ther; 2005 Sep; 314(3):972-9. PubMed ID: 15919763
[TBL] [Abstract][Full Text] [Related]
16. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides: efficient synthesis of 2'-O-methoxyethyl phosphorothioate oligonucleotides using 4,5-dicyanoimidazole. Are these oligonucleotides comparable to those synthesized using 1H-tetrazole as coupling activator?
Wang Z; Siwkowski A; Lima WF; Olsen P; Ravikumar VT
Bioorg Med Chem; 2006 Jul; 14(14):5049-60. PubMed ID: 16563772
[TBL] [Abstract][Full Text] [Related]
18. Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide.
Narayanan P; Shen L; Curtis BR; Bourdon MA; Nolan JP; Gupta S; Hoffmaster C; Zhou F; Christian B; Schaubhut JL; Greenlee S; Burel SA; Witztum JL; Engelhardt JA; Henry SP
Toxicol Sci; 2018 Aug; 164(2):613-626. PubMed ID: 29846725
[TBL] [Abstract][Full Text] [Related]
19. Application of 2'-O-(2-N-Methylcarbamoylethyl) Nucleotides in RNase H-Dependent Antisense Oligonucleotides.
Masaki Y; Iriyama Y; Nakajima H; Kuroda Y; Kanaki T; Furukawa S; Sekine M; Seio K
Nucleic Acid Ther; 2018 Oct; 28(5):307-311. PubMed ID: 30020852
[TBL] [Abstract][Full Text] [Related]
20. Determination of the impurities in drug products containing montelukast and in silico/in vitro genotoxicological assessments of sulfoxide impurity.
Emerce E; Cok I; Degim IT
Toxicol Lett; 2015 Oct; 238(2):90-9. PubMed ID: 26205398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
